Immune checkpoint proteins — proteins that help regulate immune response — were elevated on T-cells and in the blood of people with amyotrophic lateral sclerosis (ALS), a small study found, suggesting they may play a role in how the disease develops. The increases were associated with more severe…
Coya Therapeutics has launched a Phase 2 clinical trial of COYA 302 — an experimental therapy combining the signaling molecule IL-2 with CTLA4-Ig, also known as abatacept — to evaluate whether its use can slow disease progression in adults with amyotrophic lateral sclerosis (ALS) over a six-month period.
In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to help preserve daily function and breathing capacity, while also reducing signs of nerve damage and inflammation. That’s according to…
A retrospective analysis using data from two clinical studies and their extension periods showed that Radicava ORS, an oral formulation of edaravone, slows functional decline and helps adults with amyotrophic lateral sclerosis (ALS) live longer. “This analysis provides additional data to help characterize functional outcomes and potential impact of…
A veterinary medication repurposed as a treatment for amyotrophic lateral sclerosis (ALS) helped patients live longer and slowed disease progression in a long-term clinical trial. The drug, NUZ-001 from Neurizon Therapeutics, was generally safe and well tolerated in the open-label extension (NCT06177431) study, which tested the treatment in…
Neuvivo and the U.S. Food and Drug Administration (FDA) have agreed on a regulatory pathway toward the potential approval of NP001 for amyotrophic lateral sclerosis (ALS), with Phase 3 clinical testing planned for 2026. The details were agreed upon in a Type C meeting and the pivotal…
In amyotrophic lateral sclerosis (ALS), the loss of any one of four RNA-binding proteins turns off a gene called UNC13A that needs to stay active for nerve cells to communicate with each other — with three of them leading to an excess of another protein, REST — pointing to…
AUT00201, an experimental oral small molecule being developed by Autifony Therapeutics, reduced the loss of motor neurons — the nerve cells that control movement — and eased motor symptoms in a mouse model of amyotrophic lateral sclerosis (ALS), a new study showed. It was also found to improve…
The Longitude Prize on ALS is offering a total of £7.5 million (more than $10 million) to encourage scientists to use artificial intelligence (AI) to speed up the search for new treatments for amyotrophic lateral sclerosis (ALS), The entry window closes in early December. Over five years,…
Three years after its approval in the U.S., Radicava ORS (edaravone) has been prescribed by more than 1,300 healthcare providers to more than 13,500 people living with amyotrophic lateral sclerosis (ALS) in the country, according to the company that markets it. First approved as an into-the-vein infusion called…
